# Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART

> **NCT01680094** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Aarhus** · enrollment: 15 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT01680094
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-09
- **Final completion:** 2014-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01680094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01680094, "Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01680094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*